Results 31 to 40 of about 21,275,692 (207)

Non-small-cell lung cancer: how to manage EGFR-mutated disease

Drugs in Context, 2022
The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped ...
Federica Pecci, Luca Cantini, Giulio Metro, Biagio Ricciuti, Giuseppe Lamberti, Ammad Ahmad Farooqi, Rossana Berardi   +6 more
doaj   +1 more source

Non‐small cell lung cancer in China

Cancer Communications, 2022
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer
Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou   +3 more
doaj   +1 more source

CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach [PDF]

, 2008
We retrospectively studied the single and combined diagnostic value of carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA 21-1), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP), which were routinely analysed in ...
Gruber, Christine, Hatz, Rudolf, Reinmiedl, Judith, Stieber, Petra, Nagel, Dorothea   +4 more
core   +1 more source

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Drugs in Context, 2023
BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes
Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti   +5 more
doaj   +1 more source

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]

, 2006
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael, Aubert, Delphine, Flentje, Michael, Semrau, Sabine, Fietkau, Rainer, Fittipaldo, Alberto, Huber, Rudolf M., Kleine, Philip, Beckmann, Gabriele   +8 more
core   +1 more source

MYC is a metastasis gene for non-small-cell lung cancer. [PDF]

, 2009
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn, Emanuele Zanucco, Potapenko, Tamara, Korn, C., Zanucco, E., Castro, I., Inês Castro, Fatih Ceteci, Potapenko, T., Ceteci, F., Rapp, Ulf R., Luetkenhaus, Katharina, Ulf R Rapp, Korn, Christian, Tamara Potapenko, Serafin, V., Christiaan Karreman, Castro, Inês, Luetkenhaus, K., Ceteci, Fatih, Zanucco, Emanuele, Valentina Serafin, Karreman, Christiaan, Karreman, C., Serafin, Valentina, Katharina Luetkenhaus, Rapp, U. R.   +26 more
core   +2 more sources

Multifunctional role of PED/PEA15 in cell death and cell motility in human non small cell lung cancer (NSCLC) [PDF]

, 2009
PED (phosphoprotein enriched in diabetes) is a 15 KDa protein involved in many cellular pathways and human diseases, including type II diabetes and cancer. We recently reported its overexpression in breast and lung cancers, and B-cell chronic lymphocytic
Zanca, Ciro
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A., Jauch, Karl-Walter, van den Engel, N.K., Fox, B.A., Grützner, S., Hatz, R.A., Rüttinger, D., Fox, B. A., Jauch, K.-W., Winter, H., van den Engel, N. K., Schendel, D. J., Pohlac, H., Pohla, H., Schlemmer, M., Schendel, D.J.   +15 more
core   +1 more source

Staging non-small cell lung cancer [PDF]

Cancer Imaging, 2007
Patients with newly diagnosed non-small cell lung cancer (NSCLC) need accurate tumor staging in order to direct appropriate therapy and establish prognosis; the tumor is usually staged using the TNM system. The major imaging modalities currently used for staging this disease are thoracic computed tomography (CT) (including the adrenal glands) and whole
openaire   +2 more sources

Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]

, 2013
Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Hennen, Elisabeth, Olga Bermudez, Oliver Eickelberg, Olga Bermudez (410727), Ina Koch (7903), Oliver Eickelberg (153848), Eickelberg, O., Bermudez, O., Koch, I., Lindner, Michael, Elisabeth Hennen, Hennen, E., Koch, Ina, Elisabeth Hennen (410728), Bermudez, Olga, Michael Lindner, Ina Koch, Michael Lindner (383308), Lindner, M., Eickelberg, Oliver   +19 more
core   +2 more sources